動物用医薬品市場規模、シェア、動向、2031年までの世界予測

世界の動物用医薬品市場は、2026年から2031年にかけて年平均成長率（CAGR）6.3%で成長すると予測されており、これはペット分野と家畜分野の両方における着実な拡大を反映しているとMarketsandMarketsでは予測しています。この成長は、ペットの人間化の進展、慢性疾患や感染症の蔓延、そして先進的な治療法への支出増加によって支えられています。家畜分野では、生産性向上への圧力とより厳格な食品安全基準が医薬品需要を押し上げ続け、安定した中一桁台の市場成長を維持しています。

調査概要

本レポートは、製品タイプ、投与経路、製剤タイプ、適応症、動物種、流通チャネル、エンドユーザー、地域別に動物用医薬品市場を分析します。また、市場成長に影響を与える要因（促進要因、阻害要因、機会、課題など）についても考察します。市場機会と課題を分析し、市場リーダーの競争環境に関する詳細情報を提供します。さらに、本レポートは、個々の成長傾向に基づいてマイクロマーケットを分析し、5つの主要地域とその各国における市場セグメントの収益予測を提供します。

本レポートを購入する理由

• 本レポートは、既存企業だけでなく新規参入企業や中小企業にとっても、市場動向を把握し、より大きな市場シェアを獲得するのに役立ちます。本レポートを購入した企業は、以下の5つの戦略のうち1つ、または複数の戦略を組み合わせて活用できます。
• 本レポートは、以下のポイントに関する洞察を提供します。
  動物用医薬品市場の成長に影響を与える主要な促進要因、阻害要因、機会、課題の分析。
• 製品開発／イノベーション：動物用医薬品市場における最新技術、研究開発活動、製品発売に関する詳細な分析。
• 市場開発：有望な新興市場に関する包括的な情報。本レポートでは、地域別の様々なカテーテル挿入処置市場を分析。
• 市場の多様化：動物用医薬品市場における製品、未開拓地域、最新動向、投資に関する包括的な情報。
• 競合分析：動物用医薬品市場における主要企業の市場シェア、戦略、製品、流通ネットワーク、製造能力に関する詳細な分析。

Report Description

The global veterinary pharmaceuticals market is projected to grow at a CAGR of 6.3% from 2026 to 2031, reflecting steady expansion across both companion and livestock segments. Growth is supported by rising pet humanization, increasing prevalence of chronic and infectious diseases, and higher spending on advanced therapeutics. In livestock, productivity pressures and stricter food safety standards continue to drive pharmaceutical demand, sustaining consistent mid-single-digit market growth.

“By product type, the monoclonal antibodies segment is expected to witness the fastest growth rate during the forecast period.”

The monoclonal antibodies segment is expected to grow fastest in the global veterinary pharmaceuticals market, supported by a growing preference for targeted and durable treatment options, especially in companion animals. The rising burden of chronic disorders, including atopic dermatitis, osteoarthritis, and immune-mediated conditions, is boosting demand. These therapies offer precise action, fewer adverse effects, and longer dosing intervals, improving compliance. Continued investment in biologics development and the expanding premium pet care market are further driving segment expansion.

“By indication, the dermatological diseases segment has accounted for the largest share in the Veterinary pharmaceuticals market in 2025.”

The dermatological conditions segment is projected to hold the largest share of the global veterinary pharmaceuticals market in 2025, primarily due to the widespread occurrence of skin-related disorders in both companion and livestock animals. Common conditions such as atopic dermatitis, parasitic infections, fungal diseases, and bacterial skin infections require ongoing management and medication. Growing pet adoption, heightened focus on animal hygiene, and strong demand for anti-parasitic, antifungal, and anti-inflammatory treatments continue to reinforce the segment’s dominant position.

“North America dominated the global veterinary pharmaceuticals market in 2025.”

North America leads the veterinary pharmaceuticals market in 2025, supported by a mature animal healthcare ecosystem and strong purchasing power. The region records high spending on companion animal treatments and maintains a large commercial livestock base. Robust R&D investments, rapid approval pathways for innovative drugs, and the strong presence of established manufacturers further strengthen its position. Well-developed distribution networks and growing awareness of preventive animal care also contribute to its leading market position.

Breakdown of supply-side primary interviews:

• By Company Type: Tier 1 – 45%, Tier 2 – 20%, and Tier 3 – 35%
• By Designation: C-level – 35%, Director-level – 25%, and Others – 40%
• By Region: North America – 40%, Europe – 25%, APAC – 20%, Latin America – 10%, Middle East & Africa – 5%

Research Coverage

This report examines the veterinary pharmaceuticals market by product type, route of administration, formulation type, indications, animal type, distribution channel, end user, and region. It also examines factors (such as drivers, restraints, opportunities, and challenges) that affect market growth. It analyzes market opportunities and challenges and provides details on the competitive landscape for market leaders. Furthermore, the report analyzes micro-markets by their individual growth trends and forecasts market segment revenue across five main regions and their respective countries.

Reasons to Buy the Report

The report can help established firms as well as new entrants/smaller firms gauge the market pulse, which, in turn, would help them gain a greater share. Firms purchasing the report could use one or a combination of the following five strategies.

This report provides insights into the following pointers:

• Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the veterinary pharmaceuticals market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the veterinary pharmaceuticals market.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of catheterization procedures across regions.
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the veterinary pharmaceuticals market.
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the veterinary pharmaceuticals market.

Table of Contents

1 INTRODUCTION 40
1.1 STUDY OBJECTIVES 40
1.2 MARKET DEFINITION 41
1.2.1 INCLUSIONS AND EXCLUSIONS 41
1.3 MARKET SCOPE 42
1.3.1 MARKETS COVERED 42
1.3.2 YEARS CONSIDERED 43
1.4 CURRENCY CONSIDERED 43
1.5 STAKEHOLDERS 44
2 EXECUTIVE SUMMARY 45
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 45
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 46
2.3 DISRUPTIVE TRENDS IN VETERINARY PHARMACEUTICALS MARKET 47
2.4 HIGH-GROWTH SEGMENTS 48
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 49
3 PREMIUM INSIGHTS 50
3.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN VETERINARY
PHARMACEUTICALS MARKET 50
3.2 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET,
BY PRODUCT TYPE AND COUNTRY 51
3.3 VETERINARY PHARMACEUTICALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 52
3.4 VETERINARY PHARMACEUTICALS MARKET: DEVELOPING VS.
DEVELOPED ECONOMIES, 2026−2031 52
4 MARKET OVERVIEW 53
4.1 INTRODUCTION 53
4.2 MARKET DYNAMICS 53
4.2.1 DRIVERS 54
4.2.1.1 Rising companion animal ownership and pet humanization 54
4.2.1.2 Growing prevalence of infectious and dermatological diseases in animals 56
4.2.1.3 Increasing demand for animal-derived food products 57
4.2.2 RESTRAINTS 59
4.2.2.1 Growing concerns over antimicrobial resistance (AMR) 59
4.2.2.2 Stringent regulatory approval processes for veterinary drugs 59
4.2.3 OPPORTUNITIES 60
4.2.3.1 Rising demand for parasiticides and dermatology products 60
4.2.3.2 Growth potential in rural and low-income regions 60
4.2.4 CHALLENGES 61
4.2.4.1 Monitoring drug residues in food-producing animals 61
4.2.4.2 Balancing animal welfare, productivity, and compliance requirements 61
4.3 UNMET NEEDS AND WHITE SPACES 62
4.4 INTERCONNECTED MARKET AND CROSS-SECTOR OPPORTUNITIES 63
4.4.1 INTERCONNECTED MARKETS 63
4.4.2 CROSS-SECTOR OPPORTUNITIES 64
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 64
5 INDUSTRY TRENDS 65
5.1 PORTER’S FIVE FORCES ANALYSIS 65
5.1.1 THREAT OF NEW ENTRANTS 66
5.1.2 THREAT OF SUBSTITUTES 66
5.1.3 BARGAINING POWER OF SUPPLIERS 66
5.1.4 BARGAINING POWER OF BUYERS 66
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 67
5.2 MACROECONOMICS INDICATORS 67
5.2.1 INTRODUCTION 67
5.2.2 GDP TRENDS AND FORECAST 67
5.2.3 TRENDS IN GLOBAL ANIMAL HEALTHCARE INDUSTRY 68
5.2.4 TRENDS IN GLOBAL VETERINARY PHARMACEUTICALS INDUSTRY 70
5.3 VALUE CHAIN ANALYSIS 70
5.4 SUPPLY CHAIN ANALYSIS 71
5.5 ECOSYSTEM ANALYSIS 72
5.6 PRICING ANALYSIS 73
5.6.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYERS,
2023–2025 73
5.6.2 AVERAGE SELLING PRICE TREND OF FORMULATION TYPES, BY KEY PLAYERS, 2023–2025 75
5.6.3 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2023–2025 75
5.7 TRADE ANALYSIS 76
5.7.1 IMPORT DATA FOR HS CODE 30, 2021–2024 77
5.7.1.1 Import scenario (HS code 30) 77
5.7.2 EXPORT DATA FOR HS CODE 30, 2021–2024 77
5.7.3 EXPORT SCENARIO (HS CODE 30) 78
5.8 KEY CONFERENCES AND EVENTS IN 2026–2027 78
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 79
5.10 INVESTMENT AND FUNDING SCENARIO 80
5.11 CASE STUDY ANALYSIS 80
5.11.1 ZOETIS INC. 80
5.11.2 BOEHRINGER INGELHEIM ANIMAL HEALTH 81
5.11.3 MERCK ANIMAL HEALTH 81
5.11.4 ELANCO ANIMAL HEALTH 81
5.11.5 CEVA SANTE ANIMALE 82
5.12 IMPACT OF 2025 US TARIFF – VETERINARY PHARMACEUTICALS MARKET 82
5.12.1 INTRODUCTION 82
5.12.2 KEY TARIFF RATES 83
5.12.3 PRICE IMPACT ANALYSIS 83
5.12.4 IMPACT ON REGIONS 83
5.12.4.1 North America 83
5.12.4.2 Europe 84
5.12.4.3 Asia Pacific 84
5.12.5 IMPACT ON END-USE INDUSTRIES 84
5.12.5.1 Veterinary hospitals & clinics 84
5.12.5.2 Home care settings 84
5.12.5.3 Livestock farms 84
5.12.5.4 Rescue centers & NGOs 85
5.12.5.5 Other end users 85
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 86
6.1 TECHNOLOGY ANALYSIS 86
6.1.1 KEY EMERGING TECHNOLOGIES 86
6.1.1.1 Controlled release formulation 86
6.1.1.2 Biologics and monoclonal antibodies 86
6.1.2 COMPLEMENTARY TECHNOLOGIES 86
6.1.2.1 Digital health and telemedicine platforms 86
6.1.2.2 Veterinary biomarker analysis 87
6.1.3 ADJACENT TECHNOLOGIES 87
6.1.3.1 Wearable animal health monitoring devices 87
6.1.3.2 Stem cell therapy and regenerative medicine 87
6.2 TECHNOLOGY/PRODUCT ROADMAP 87
6.3 PATENT ANALYSIS 89
6.3.1 PUBLICATION TRENDS FOR VETERINARY PHARMACEUTICALS 89
6.3.2 INSIGHTS ON PATENT PUBLICATION TRENDS, TOP APPLICANTS AND JURISDICTION FOR VETERINARY PHARMACEUTICALS MARKET, JANUARY 2015–DECEMBER 2025 89
6.3.3 LIST OF MAJOR PATENTS, 2023–2025 91
6.4 FUTURE APPLICATIONS 92
6.4.1 PRECISION LIVESTOCK HEALTH MANAGEMENT 92
6.4.2 ONCOLOGY AND CHRONIC DISEASE MANAGEMENT 92
6.4.3 REPRODUCTIVE AND FERTILITY ENHANCEMENT IN LIVESTOCK 92
6.4.4 INTEGRATED DISEASE SURVEILLANCE AND OUTBREAK CONTROL 92
6.5 IMPACT OF GEN AI ON VETERINARY PHARMACEUTICALS MARKET 93
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 94
7.1 REGIONAL REGULATIONS AND COMPLIANCE 94
7.1.1 REGULATORY FRAMEWORK 94
7.1.1.1 North America 94
7.1.1.2 Europe 95
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96
7.1.3 INDUSTRY STANDARDS 99
7.1.3.1 VICH Guidelines (International Co-operation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products) 99
7.1.3.2 Good Manufacturing Practice (GMP) Standards – PIC/S Guide (PE 009 series) 99
7.1.3.3 Codex Alimentarius Standards for Veterinary Drug Residues (CXM 2 – Maximum Residue Limits) 100
7.2 SUSTAINABILITY INITIATIVES 100
7.2.1 ECO-FRIENDLY AND RECYCLABLE MATERIALS IN VETERINARY PHARMACEUTICALS MARKET 100
7.2.1.1 Virbac – Eco-pack to reduce single-use plastic in veterinary products 100
7.2.1.2 Boehringer Ingelheim Animal Health – Renewable energy-powered manufacturing 100
7.2.1.3 Boehringer Ingelheim – Recyclable veterinary delivery device (Aservo, EquiHaler) 101
7.3 CERTIFICATIONS, LABELING, ECO-STANDARDS 101
8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR 102
8.1 DECISION-MAKING PROCESS 102
8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA 103
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 103
8.2.2 BUYING CRITERIA 103
8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES 104
8.4 UNMET NEEDS IN VARIOUS END-USE SETTINGS 105
8.5 MARKET PROFITABILITY 106
8.5.1 PRODUCT INNOVATION AND DIFFERENTIATION 106
8.5.2 EXPANSION OF COMPANION ANIMAL HEALTHCARE SPENDING 106
8.5.3 OPERATIONAL SCALE AND DISTRIBUTION EFFICIENCY 106
9 VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE 107
9.1 INTRODUCTION 108
9.1.1 VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS) 108
9.2 DRUGS 109
9.2.1 ANTI-BACTERIAL DRUGS 110
9.2.1.1 Routine use in livestock and companion animals underpins strong market share and steady growth 110
9.2.2 ANTI-FUNGAL DRUGS 112
9.2.2.1 Limited approvals and off-label systemic use result in smaller but clinically essential segment 112
9.2.3 ANTI-VIRAL DRUGS 113
9.2.3.1 Low current penetration but rising research interest driven by outbreak response and targeted therapies 113
9.2.4 ANTI-INFLAMMATORY DRUGS 114
9.2.4.1 Rising surgical volumes and chronic pain management drive stable double-digit market share 114
9.2.5 ANTI-PARASITIC DRUGS 115
9.2.5.1 High parasitic burden and preventive care practices sustain market share and strong growth trajectory 115
9.2.6 ANTI-CANCER DRUGS 116
9.2.6.1 Increasing pet oncology awareness and advanced therapeutics to fuel growth from small base 116
9.2.7 CARDIOVASCULAR AND RENAL DRUGS 117
9.2.7.1 Rising diagnosis of chronic heart and kidney disorders supports steady mid-single-digit market share 117
9.2.8 GASTROINTESTINAL DRUGS 118
9.2.8.1 High incidence of digestive disorders and dietary transitions drive sustained demand 118
9.2.9 OTHER DRUGS 119
9.3 MONOCLONAL ANTIBODIES 120
9.3.1 TARGETED BIOLOGICS AND RISING COMPANION ANIMAL THERAPEUTICS TO DRIVE DEMAND 120
9.4 IMMUNOMODULATORS 121
9.4.1 INCREASING FOCUS ON IMMUNE-MEDIATED DISEASES AND PREVENTIVE HEALTH TO SUPPORT GRADUAL EXPANSION FROM SMALLER BASE 121
9.5 MEDICATED FEED ADDITIVES 122
9.5.1 AMINO ACIDS 124
9.5.1.1 Protein optimization and feed cost efficiency to drive demand 124
9.5.2 ENZYMES 125
9.5.2.1 Improved nutrient digestibility and cost optimization to support steady adoption 125
9.5.3 VITAMINS AND MINERALS 126
9.5.3.1 Essential micronutrient supplementation ensures largest market share 126
9.5.4 OTHER MEDICATED FEED ADDITIVES 127
10 VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION 128
10.1 INTRODUCTION 129
10.2 ORAL 129
10.2.1 EASE OF DOSING AND HIGH COMPLIANCE IN COMPANION AND LIVESTOCK ANIMALS 129

10.3 PARENTERAL 131
10.3.1 RAPID THERAPEUTIC ACTION AND HIGHER BIOAVAILABILITY IN
CRITICAL CARE AND PRODUCTION SETTINGS 131
10.4 TOPICAL 132
10.4.1 RISING DERMATOLOGY CASES AND DEMAND FOR LOCALIZED,
NON-INVASIVE TREATMENTS 132
10.5 OTHER ROUTES OF ADMINISTRATION 133
11 VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE 134
11.1 INTRODUCTION 135
11.2 SOLID 135
11.2.1 DOSING STABILITY, COST EFFICIENCY, AND EASE OF LARGE-SCALE ADMINISTRATION IN LIVESTOCK AND COMPANION ANIMALS 135
11.3 LIQUID 137
11.3.1 RAPID ABSORPTION, FLEXIBLE DOSING, AND SUITABILITY FOR INJECTABLES AND ORAL SUSPENSIONS 137
11.4 SEMI-SOLID 138
11.4.1 RISING DERMATOLOGY CASES AND INCREASING COMPANION
ANIMAL CARE EXPENDITURE 138
11.5 AEROSOL/SPRAY 139
11.5.1 CONVENIENCE, TARGETED DELIVERY, AND REDUCED CROSS-CONTAMINATION RISK 139
11.6 PREMIX FORMULATIONS 140
11.6.1 DEMAND FOR MEDICATED FEED AND PREVENTIVE HERD-LEVEL DISEASE MANAGEMENT TO DRIVE MARKET 140
12 VETERINARY PHARMACEUTICALS MARKET, BY INDICATION 141
12.1 INTRODUCTION 142
12.2 INFECTIOUS DISEASES 142
12.2.1 ZOONOTIC RISK AND LIVESTOCK DISEASE CONTROL PROGRAMS TO DRIVE MARKET 142
12.3 DERMATOLOGICAL DISEASES 143
12.3.1 RISING CHRONIC SKIN CONDITIONS AND PREMIUM COMPANION ANIMAL SPENDING TO DRIVE MARKET 143
12.4 PAIN MANAGEMENT 145
12.4.1 RISING SURGICAL PROCEDURES AND AGING PET POPULATION TO DRIVE MARKET 145
12.5 CARDIOVASCULAR AND RENAL DISEASES 146
12.5.1 INCREASED DIAGNOSIS IN AGING COMPANION ANIMALS TO DRIVE MARKET 146
12.6 GASTROINTESTINAL DISEASES 147
12.6.1 HIGH PREVALENCE OF ENTERIC INFECTIONS AND DIETARY DISORDERS TO DRIVE MARKET 147
12.7 OTHER INDICATIONS 148

13 VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE 149
13.1 INTRODUCTION 150
13.2 COMPANION ANIMALS 150
13.2.1 DOGS 153
13.2.1.1 Increasing population and adoption of dogs to drive market 153
13.2.2 CATS 155
13.2.2.1 Emerging trends in feline pharmaceuticals to boost market 155
13.2.3 HORSES 157
13.2.3.1 Higher risk of traumatic injuries in horses to drive demand for veterinary pharmaceutical products 157
13.2.4 OTHER COMPANION ANIMALS 158
13.3 LIVESTOCK ANIMALS 160
13.3.1 CATTLE 162
13.3.1.1 Economic importance of dairy and beef cattle to drive growth 162
13.3.2 SWINE 164
13.3.2.1 Growing surgical volume for acute conditions in swine to drive market 164
13.3.3 POULTRY 166
13.3.3.1 Growing focus on infection prevention and flock health management to drive market 166
13.3.4 OTHER LIVESTOCK ANIMALS 167
14 VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL 169
14.1 INTRODUCTION 170
14.2 VETERINARY HOSPITAL PHARMACIES 170
14.2.1 HIGH IMPORTANCE AND BETTER OPPORTUNITIES IN ON-FARM VETERINARY PHARMACEUTICALS TO DRIVE MARKET 170
14.3 RETAIL PHARMACIES 172
14.3.1 RETAIL PHARMACIES TO AID ACCESSIBILITY AND MARKET REACH IN VETERINARY PHARMACEUTICALS 172
14.4 ONLINE PHARMACIES 174
14.4.1 CONVENIENCE AND ACCESSIBILITY TO AUGMENT MARKET GROWTH 174
14.5 DIRECT SALES 175
14.5.1 DIRECT SALES TO STRENGTHEN MANUFACTURER-TO-CUSTOMER CONNECTIONS 175
15 VETERINARY PHARMACEUTICALS MARKET, BY END USER 177
15.1 INTRODUCTION 178
15.2 VETERINARY HOSPITALS & CLINICS 178
15.2.1 FIRST POINT OF CONTACT FOR ANIMAL OWNERS AND LIVESTOCK CAREGIVERS 178
15.3 LIVESTOCK FARMS 180
15.3.1 GROWING IMPORTANCE AND OPPORTUNITIES IN ON-FARM ANIMAL CARE 180
15.4 HOME CARE SETTINGS 181
15.4.1 RISING PET EXPENDITURE TO PROPEL SEGMENT GROWTH 181
15.5 OTHER END USERS 182
16 VETERINARY PHARMACEUTICALS MARKET, BY REGION 183
16.1 INTRODUCTION 184
16.2 NORTH AMERICA 187
16.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 187
16.2.2 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS) 190
16.2.3 US 195
16.2.3.1 Surge in animal healthcare expenditure to boost market 195
16.2.4 CANADA 201
16.2.4.1 Growing pet population and advanced veterinary services to drive market 201
16.3 EUROPE 207
16.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 208
16.3.2 EUROPE: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS) 210
16.3.3 GERMANY 214
16.3.3.1 Increased focus on animal welfare to drive demand for veterinary pharmaceutical products 214
16.3.4 UK 220
16.3.4.1 Increasing pet ownership to propel market 220
16.3.5 FRANCE 226
16.3.5.1 High standards of veterinary care to provide attractive growth opportunities for market players 226
16.3.6 ITALY 233
16.3.6.1 Growing pet owner awareness and increasing livestock population to drive market 233
16.3.7 SPAIN 238
16.3.7.1 Increasing awareness of animal health to drive market 238
16.3.8 REST OF EUROPE 244
16.4 ASIA PACIFIC 249
16.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 250
16.4.2 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS) 253
16.4.3 JAPAN 257
16.4.3.1 Surge in pet care expenditure and growing adoption of companion animals to drive market 257
16.4.4 CHINA 263
16.4.4.1 Increasing animal healthcare expenditure and advancements in veterinary medicines to drive market 263
16.4.5 INDIA 269
16.4.5.1 Increasing livestock population to propel market growth 269

16.4.6 AUSTRALIA 275
16.4.6.1 Growing companion animal ownership and rise in animal health awareness to support market growth 275
16.4.7 SOUTH KOREA 281
16.4.7.1 Growing pet ownership and advancements in veterinary medicine to favor market growth 281
16.4.8 PHILIPPINES 288
16.4.8.1 Tourism-linked pet culture and veterinary advancements to fuel market 288
16.4.9 REST OF ASIA PACIFIC 293
16.5 LATIN AMERICA 298
16.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 299
16.5.2 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS) 300
16.5.3 BRAZIL 305
16.5.3.1 Growing pet population and rising disposable incomes to drive market 305
16.5.4 MEXICO 312
16.5.4.1 Robust livestock base and growing companion animal care to drive market 312
16.5.5 REST OF LATIN AMERICA 317
16.6 MIDDLE EAST & AFRICA 322
16.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 323
16.6.2 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS) 324
16.7 GCC COUNTRIES 328
16.7.1 KINGDOM OF SAUDI ARABIA (KSA) 335
16.7.1.1 Vision 2030 investments to drive market 335
16.7.2 UNITED ARAB EMIRATES (UAE) 341
16.7.2.1 Increasing adoption of advanced diagnostic technologies to contribute to market growth 341
16.7.3 REST OF GCC COUNTRIES 346
16.7.4 REST OF MIDDLE EAST & AFRICA 351
17 COMPETITIVE LANDSCAPE 357
17.1 INTRODUCTION 357
17.1.1 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2023–2026 357
17.2 REVENUE ANALYSIS, 2023–2025 358
17.3 MARKET SHARE ANALYSIS, 2025 359
17.3.1 US: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025 361
17.3.2 EUROPE: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025 362
17.4 PRODUCT/BRAND COMPARISON 363
17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 364
17.5.1 STARS 364
17.5.2 EMERGING LEADERS 364
17.5.3 PERVASIVE PLAYERS 364
17.5.4 PARTICIPANTS 364
17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 366
17.5.5.1 Company footprint 366
17.5.5.2 Region footprint 367
17.5.5.3 Product type footprint 368
17.5.5.4 Route of administration footprint 369
17.5.5.5 Indication footprint 370
17.5.5.6 End user footprint 371
17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 372
17.6.1 PROGRESSIVE COMPANIES 372
17.6.2 RESPONSIVE COMPANIES 372
17.6.3 DYNAMIC COMPANIES 372
17.6.4 STARTING BLOCKS 372
17.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 374
17.6.5.1 Detailed list of key startups/SMEs 374
17.6.5.2 Competitive benchmarking of key startups/SMEs 375
17.7 COMPANY VALUATION AND FINANCIAL METRICS 376
17.8 COMPETITIVE SCENARIO 376
17.8.1 PRODUCT LAUNCHES & APPROVALS 377
17.8.2 DEALS 378
17.8.3 EXPANSIONS 379
17.8.4 OTHER DEVELOPMENTS 379
18 COMPANY PROFILES 380
18.1 KEY PLAYERS 380
18.1.1 ZOETIS INC. 380
18.1.1.1 Business overview 380
18.1.1.2 Products offered 382
18.1.1.3 Recent developments 383
18.1.1.3.1 Product launches & approvals 383
18.1.1.3.2 Expansions 384
18.1.1.3.3 Other developments 384
18.1.1.4 MnM view 385
18.1.1.4.1 Right to win 385
18.1.1.4.2 Strategic choices 385
18.1.1.4.3 Weaknesses and competitive threats 385
18.1.2 MERCK & CO., INC 386
18.1.2.1 Business overview 386
18.1.2.2 Products offered 387
18.1.2.3 Recent developments 388
18.1.2.3.1 Product launches & approvals 388
18.1.2.3.2 Deals 389
18.1.2.3.3 Expansions 390
18.1.2.4 MnM view 390
18.1.2.4.1 Right to win 390
18.1.2.4.2 Strategic choices 391
18.1.2.4.3 Weaknesses and competitive threats 391
18.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 392
18.1.3.1 Business overview 392
18.1.3.2 Products offered 393
18.1.3.3 Recent developments 394
18.1.3.3.1 Product launches & approvals 394
18.1.3.3.2 Deals 395
18.1.3.3.3 Expansions 396
18.1.3.4 MnM view 397
18.1.3.4.1 Right to win 397
18.1.3.4.2 Strategic choices 397
18.1.3.4.3 Weaknesses and competitive threats 397
18.1.4 ELANCO ANIMAL HEALTH INCORPORATED 398
18.1.4.1 Business overview 398
18.1.4.2 Products offered 399
18.1.4.3 Recent developments 401
18.1.4.3.1 Product launches & approvals 401
18.1.4.3.2 Expansions 402
18.1.4.3.3 Other developments 403
18.1.4.4 MnM view 403
18.1.4.4.1 Right to win 403
18.1.4.4.2 Strategic choices 403
18.1.4.4.3 Weaknesses and competitive threats 403
18.1.5 VIRBAC 404
18.1.5.1 Business overview 404
18.1.5.2 Products offered 405
18.1.5.3 Recent developments 406
18.1.5.3.1 Product launches & approvals 406
18.1.5.3.2 Deal 407
18.1.5.3.3 Expansions 408
18.1.5.4 MnM view 408
18.1.5.4.1 Right to win 408
18.1.5.4.2 Strategic choices 408
18.1.5.4.3 Weaknesses and competitive threats 408

18.1.6 CEVA 409
18.1.6.1 Business overview 409
18.1.6.2 Products offered 410
18.1.6.3 Recent developments 410
18.1.6.3.1 Deals 410
18.1.6.3.2 Expansions 411
18.1.7 VETOQUINOL 412
18.1.7.1 Business overview 412
18.1.7.2 Products offered 413
18.1.7.3 Recent developments 415
18.1.7.3.1 Product launches & approvals 415
18.1.7.3.2 Deals 415
18.1.8 DECHRA PHARMACEUTICALS PLC 416
18.1.8.1 Business overview 416
18.1.8.2 Products offered 416
18.1.8.3 Recent developments 418
18.1.8.3.1 Product launches & approvals 418
18.1.8.3.2 Deals 419
18.1.8.3.3 Other developments 419
18.1.9 NORBROOK 420
18.1.9.1 Business overview 420
18.1.9.2 Products offered 420
18.1.9.3 Recent developments 423
18.1.9.3.1 Product launches & approvals 423
18.1.9.3.2 Deals 423
18.1.9.3.3 Expansions 424
18.1.9.3.4 Other developments 424
18.1.10 BIMEDA CORPORATE 425
18.1.10.1 Business overview 425
18.1.10.2 Products offered 425
18.1.10.3 Recent developments 427
18.1.10.3.1 Product launches & approvals 427
18.1.10.3.2 Deals 428
18.1.10.3.3 Expansions 428
18.1.11 HESTER BIOSCIENCES LIMITED 429
18.1.11.1 Business overview 429
18.1.11.2 Products offered 430
18.1.12 INDIAN IMMUNOLOGICALS LTD. 432
18.1.12.1 Business overview 432
18.1.12.2 Products offered 433

18.1.13 ANIMALCARE GROUP PLC 435
18.1.13.1 Business overview 435
18.1.13.2 Products offered 437
18.1.13.3 Recent developments 438
18.1.13.3.1 Deals 438
18.1.13.3.2 Product launches & approvals 439
18.1.14 KYORITSU SEIYAKU CORPORATION 440
18.1.14.1 Business overview 440
18.1.14.2 Products offered 440
18.1.14.3 Recent developments 442
18.1.14.3.1 Product launches & approvals 442
18.1.14.3.2 Deals 443
18.1.15 CALIER 444
18.1.15.1 Business overview 444
18.1.15.2 Products offered 444
18.1.15.3 Recent developments 446
18.1.15.3.1 Product launches & approvals 446
18.2 OTHER PLAYERS 447
18.2.1 DOPHARMA 447
18.2.2 PHARMGATE ANIMAL HEALTH 448
18.2.3 BIOVETA, A.S. 449
18.2.4 NEXTMUNE 450
18.2.5 TRIVIUMVET 451
18.2.6 DOMES PHARMA 452
18.2.7 UNIVET LIMITED 453
18.2.8 CENAVISA, S.L. 454
18.2.9 FATRO S.P.A. 455
18.2.10 CHANELLE PHARMA 456
19 RESEARCH METHODOLOGY 457
19.1 RESEARCH DATA 457
19.1.1 SECONDARY DATA 458
19.1.1.1 Key data from secondary sources 459
19.1.2 PRIMARY DATA 460
19.1.2.1 Key data from primary sources 461
19.1.2.2 Key industry insights 461
19.1.2.3 Key industry insights 462
19.2 MARKET SIZE ESTIMATION 462
19.3 GROWTH FORECAST 466
19.3.1 KEY INDUSTRY INSIGHTS 468
19.4 MARKET BREAKDOWN AND DATA TRIANGULATION 469

19.5 RESEARCH ASSUMPTIONS 470
19.6 RESEARCH LIMITATIONS 470
19.7 RISK ASSESSMENT 470
20 APPENDIX 471
20.1 DISCUSSION GUIDE 471
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 478
20.3 CUSTOMIZATION OPTIONS 480
20.3.1 PRODUCT ANALYSIS 480
20.3.2 US END USER ANALYSIS 480
20.3.3 GEOGRAPHIC ANALYSIS 480
20.3.4 COMPANY INFORMATION 480
20.3.5 REGIONAL/COUNTRY LEVEL MARKET SHARE ANALYSIS 480
20.3.6 COUNTRY LEVEL VOLUME ANALYSIS BY PRODUCT TYPE 480
20.3.7 BY PRODUCT TYPE MARKET SHARE ANALYSIS (TOP 5 PLAYERS) 480
20.3.8 ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST 480
20.4 RELATED REPORTS 481
20.5 AUTHOR DETAILS 482

LIST OF TABLES

TABLE 1 STANDARD CURRENCY CONVERSION RATES (UNIT OF USD) 43
TABLE 2 PET (DOGS AND CATS) OWNERSHIP STATISTICS IN US, 2024 55
TABLE 3 COMPANION ANIMAL POPULATION STATISTICS, BY REGION 55
TABLE 4 RECENT GOVERNMENT-REPORTED INDICATORS 57
TABLE 5 TRENDS IN CONSUMPTION OF MEAT & MILK IN DEVELOPED &
EMERGING ECONOMIES 57
TABLE 6 ASIA: COUNTRY-LEVEL CONSUMPTION OF ANIMAL-DERIVED
FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS) 58
TABLE 7 ASIA: COUNTRY-LEVEL PRODUCTION OF ANIMAL-DERIVED FOOD
PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS) 58
TABLE 8 UNMET CUSTOMER NEEDS AND WHITE SPACES IN VETERINARY PHARMACEUTICALS MARKET. 62
TABLE 9 INTERCONNECTED MARKETS IN VETERINARY PHARMACEUTICALS MARKET 63
TABLE 10 CROSS-SECTOR MARKETS IN VETERINARY PHARMACEUTICALS MARKET 64
TABLE 11 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 64
TABLE 12 IMPACT OF PORTER’S FIVE FORCES ON VETERINARY PHARMACEUTICALS MARKET 66
TABLE 13 GDP TREND AND FORECAST, BY COUNTRY, 2021–2030 (USD BILLION) 67
TABLE 14 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYERS, 2023–2025 74
TABLE 15 AVERAGE SELLING PRICE TREND OF FORMULATION TYPES,
BY KEY PLAYERS, 2023–2025 75
TABLE 16 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2023–2025 76
TABLE 17 IMPORT DATA FOR HS CODE 30, BY COUNTRY, 2021–2024 (USD MILLION) 77
TABLE 18 EXPORT DATA FOR HS CODE 30, BY COUNTRY, 2021–2024 (USD MILLION) 78
TABLE 19 DETAILED LIST OF CONFERENCES AND EVENTS, 2026–2027 78
TABLE 20 US ADJUSTED RECIPROCAL TARIFF RATES 83
TABLE 21 TECHNOLOGY/PRODUCT ROADMAP 88
TABLE 22 VETERINARY PHARMACEUTICALS MARKET: LIST OF MAJOR PATENTS,
JANUARY 2023–DECEMBER 2025 91
TABLE 23 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 96
TABLE 24 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 97
TABLE 25 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 98
TABLE 26 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT
AGENCIES, AND OTHER ORGANIZATIONS 99
TABLE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR
VETERINARY PHARMACEUTICAL PRODUCTS 103
TABLE 28 KEY BUYING CRITERIA FOR TOP THREE END USERS 104
TABLE 29 VETERINARY PHARMACEUTICALS MARKET: UNMET NEEDS IN
KEY END-USE SETTINGS 106
TABLE 30 VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE,
2024–2031 (THOUSAND UNITS) 108
TABLE 31 VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 108
TABLE 32 VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2024–2031 (USD MILLION) 109
TABLE 33 VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 110
TABLE 34 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-BACTERIAL DRUGS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 111
TABLE 35 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-FUNGAL DRUGS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 112
TABLE 36 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-VIRAL DRUGS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 113
TABLE 37 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-INFLAMMATORY DRUGS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 114
TABLE 38 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-PARASITIC DRUGS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 115
TABLE 39 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-CANCER DRUGS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 116
TABLE 40 VETERINARY PHARMACEUTICALS MARKET FOR CARDIOVASCULAR AND RENAL DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 117
TABLE 41 VETERINARY PHARMACEUTICALS MARKET FOR GASTROINTESTINAL DRUGS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 118
TABLE 42 VETERINARY PHARMACEUTICALS MARKET FOR OTHER DRUGS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 119
TABLE 43 VETERINARY PHARMACEUTICALS MARKET FOR MONOCLONAL ANTIBODIES,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 120
TABLE 44 VETERINARY PHARMACEUTICALS MARKET FOR IMMUNOMODULATORS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 121
TABLE 45 VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES,
BY TYPE, 2024–2031 (USD MILLION) 122
TABLE 46 VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 123
TABLE 47 VETERINARY PHARMACEUTICALS MARKET FOR AMINO ACIDS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 124
TABLE 48 VETERINARY PHARMACEUTICALS MARKET FOR ENZYMES, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 125
TABLE 49 VETERINARY PHARMACEUTICALS MARKET FOR VITAMINS AND MINERALS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 126
TABLE 50 VETERINARY PHARMACEUTICALS MARKET FOR OTHER MEDICATED FEED ADDITIVES, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 127
TABLE 51 VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION,
2024–2031 (USD MILLION) 129
TABLE 52 VETERINARY PHARMACEUTICALS MARKET FOR ORAL, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 130
TABLE 53 VETERINARY PHARMACEUTICALS MARKET FOR PARENTERAL,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 131
TABLE 54 VETERINARY PHARMACEUTICALS MARKET FOR TOPICAL, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 132
TABLE 55 VETERINARY PHARMACEUTICALS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 133
TABLE 56 VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE,
2024–2031 (USD MILLION) 135
TABLE 57 VETERINARY PHARMACEUTICALS MARKET FOR SOLID, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 136
TABLE 58 VETERINARY PHARMACEUTICALS MARKET FOR LIQUID, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 137
TABLE 59 VETERINARY PHARMACEUTICALS MARKET FOR SEMI-SOLID, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 138
TABLE 60 VETERINARY PHARMACEUTICALS MARKET FOR AEROSOL/SPRAY,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 139
TABLE 61 VETERINARY PHARMACEUTICALS MARKET FOR PREMIX FORMULATIONS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 140
TABLE 62 VETERINARY PHARMACEUTICALS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 142
TABLE 63 VETERINARY PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 143
TABLE 64 VETERINARY PHARMACEUTICALS MARKET FOR DERMATOLOGICAL DISEASES,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 144
TABLE 65 VETERINARY PHARMACEUTICALS MARKET FOR PAIN MANAGEMENT,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 145
TABLE 66 VETERINARY PHARMACEUTICALS MARKET FOR CARDIOVASCULAR AND RENAL DISEASES, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 146
TABLE 67 VETERINARY PHARMACEUTICALS MARKET FOR GASTROINTESTINAL DISEASES,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 147
TABLE 68 VETERINARY PHARMACEUTICALS MARKET FOR OTHER INDICATIONS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 148
TABLE 69 VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 150
TABLE 70 VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 151
TABLE 71 VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 152
TABLE 72 VETERINARY PHARMACEUTICALS MARKET FOR DOGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 154
TABLE 73 VETERINARY PHARMACEUTICALS MARKET FOR CATS, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 156
TABLE 74 VETERINARY PHARMACEUTICALS MARKET FOR HORSES, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 158
TABLE 75 VETERINARY PHARMACEUTICALS MARKET FOR OTHER COMPANION ANIMALS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 159
TABLE 76 VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 160
TABLE 77 VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 161
TABLE 78 VETERINARY PHARMACEUTICALS MARKET FOR CATTLE, BY COUNTRY/ REGION, 2024–2031 (USD MILLION) 163
TABLE 79 VETERINARY PHARMACEUTICALS MARKET FOR SWINE, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 165
TABLE 80 VETERINARY PHARMACEUTICALS MARKET FOR POULTRY, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 167
TABLE 81 VETERINARY PHARMACEUTICALS MARKET FOR OTHER LIVESTOCK ANIMALS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 168
TABLE 82 VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL,
2024–2031 (USD MILLION) 170
TABLE 83 VETERINARY PHARMACEUTICALS MARKET FOR VETERINARY HOSPITAL PHARMACIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION) 171
TABLE 84 VETERINARY PHARMACEUTICALS MARKET FOR RETAIL PHARMACIES,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 173
TABLE 85 VETERINARY PHARMACEUTICALS MARKET FOR ONLINE PHARMACIES,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 175
TABLE 86 VETERINARY PHARMACEUTICALS MARKET FOR DIRECT SALES,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 176
TABLE 87 VETERINARY PHARMACEUTICALS MARKET, BY END USER,
2024–2031 (USD MILLION) 178
TABLE 88 VETERINARY PHARMACEUTICALS MARKET FOR VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 89 VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK FARMS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 180
TABLE 90 VETERINARY PHARMACEUTICALS MARKET FOR HOME CARE SETTINGS,
BY COUNTRY/REGION, 2024–2031 (USD MILLION) 181
TABLE 91 VETERINARY PHARMACEUTICALS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 92 VETERINARY PHARMACEUTICALS MARKET, BY REGION,
2024–2031 (USD MILLION) 185
TABLE 93 VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY/REGION,
2024–2031 (USD MILLION) 186
TABLE 94 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 189
TABLE 95 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 190
TABLE 96 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS) 190
TABLE 97 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS,
BY TYPE, 2024–2031 (USD MILLION) 191
TABLE 98 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 191
TABLE 99 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 192
TABLE 100 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 192
TABLE 101 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 193
TABLE 102 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 193
TABLE 103 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 194
TABLE 104 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 194
TABLE 105 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 195
TABLE 106 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET,
BY END USER, 2024–2031 (USD MILLION) 195
TABLE 107 US: KEY MACRO INDICATORS 196
TABLE 108 US: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 197
TABLE 109 US: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2024–2031 (USD MILLION) 197
TABLE 110 US: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 198
TABLE 111 US: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 198
TABLE 112 US: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE,
2024–2031 (USD MILLION) 199
TABLE 113 US: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 199
TABLE 114 US: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 200
TABLE 115 US: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 200
TABLE 116 US: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 200
TABLE 117 US: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 201
TABLE 118 US: VETERINARY PHARMACEUTICALS MARKET, BY END USER,
2024–2031 (USD MILLION) 201
TABLE 119 CANADA: KEY MACRO INDICATORS 202
TABLE 120 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 202
TABLE 121 CANADA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2024–2031 (USD MILLION) 203
TABLE 122 CANADA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 203
TABLE 123 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 204
TABLE 124 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 204
TABLE 125 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 205
TABLE 126 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 205
TABLE 127 CANADA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 206
TABLE 128 CANADA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 206
TABLE 129 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 207
TABLE 130 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY END USER,
2024–2031 (USD MILLION) 207
TABLE 131 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 209
TABLE 132 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 209
TABLE 133 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE,
2024–2031 (THOUSAND UNITS) 210
TABLE 134 EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2024–2031 (USD MILLION) 210
TABLE 135 EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 211
TABLE 136 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 211
TABLE 137 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 212
TABLE 138 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 212
TABLE 139 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 213
TABLE 140 EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 213
TABLE 141 EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 213
TABLE 142 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 214
TABLE 143 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY END USER,
2024–2031 (USD MILLION) 214
TABLE 144 GERMANY: KEY MACRO INDICATORS 215
TABLE 145 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 215
TABLE 146 GERMANY: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS,
BY TYPE, 2024–2031 (USD MILLION) 216
TABLE 147 GERMANY: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 216
TABLE 148 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 217
TABLE 149 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 217
TABLE 150 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 218
TABLE 151 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 218
TABLE 152 GERMANY: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 219
TABLE 153 GERMANY: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 219
TABLE 154 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 220
TABLE 155 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY END USER,
2024–2031 (USD MILLION) 220
TABLE 156 UK: KEY MACRO INDICATORS 221
TABLE 157 UK: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 221
TABLE 158 UK: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2024–2031 (USD MILLION) 222
TABLE 159 UK: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 222
TABLE 160 UK: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 223
TABLE 161 UK: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE,
2024–2031 (USD MILLION) 223
TABLE 162 UK: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 224
TABLE 163 UK: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 224
TABLE 164 UK: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 225
TABLE 165 UK: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 225
TABLE 166 UK: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 226
TABLE 167 UK: VETERINARY PHARMACEUTICALS MARKET, BY END USER,
2024–2031 (USD MILLION) 226
TABLE 168 FRANCE: KEY MACRO INDICATORS 227
TABLE 169 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 227
TABLE 170 FRANCE: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2024–2031 (USD MILLION) 228
TABLE 171 FRANCE: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 228
TABLE 172 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 229
TABLE 173 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 229
TABLE 174 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 230
TABLE 175 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 230
TABLE 176 FRANCE: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 231
TABLE 177 FRANCE: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 231
TABLE 178 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 232
TABLE 179 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY END USER,
2024–2031 (USD MILLION) 232
TABLE 180 ITALY: KEY MACRO INDICATORS 233
TABLE 181 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 233
TABLE 182 ITALY: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2024–2031 (USD MILLION) 234
TABLE 183 ITALY: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 234
TABLE 184 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 235
TABLE 185 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE,
2024–2031 (USD MILLION) 235
TABLE 186 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 236
TABLE 187 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 236
TABLE 188 ITALY: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 237
TABLE 189 ITALY: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 237
TABLE 190 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 238
TABLE 191 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY END USER,
2024–2031 (USD MILLION) 238
TABLE 192 SPAIN: KEY MACRO INDICATORS 239
TABLE 193 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 239
TABLE 194 SPAIN: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2024–2031 (USD MILLION) 240
TABLE 195 SPAIN: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 240
TABLE 196 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 241
TABLE 197 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE,
2024–2031 (USD MILLION) 241
TABLE 198 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 242
TABLE 199 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 242
TABLE 200 SPAIN: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 243
TABLE 201 SPAIN: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 243
TABLE 202 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 244
TABLE 203 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY END USER,
2024–2031 (USD MILLION) 244
TABLE 204 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 245
TABLE 205 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS,
BY TYPE, 2024–2031 (USD MILLION) 245
TABLE 206 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 246
TABLE 207 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 246
TABLE 208 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 247
TABLE 209 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 247
TABLE 210 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 248
TABLE 211 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 248
TABLE 212 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 248
TABLE 213 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 249
TABLE 214 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION) 249
TABLE 215 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 252
TABLE 216 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 252
TABLE 217 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS) 253
TABLE 218 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 253
TABLE 219 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 254
TABLE 220 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 254
TABLE 221 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 255
TABLE 222 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 255
TABLE 223 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 256
TABLE 224 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 256
TABLE 225 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 256
TABLE 226 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 257
TABLE 227 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY END USER,
2024–2031 (USD MILLION) 257
TABLE 228 JAPAN: KEY MACRO INDICATORS 258
TABLE 229 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 258
TABLE 230 JAPAN: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2024–2031 (USD MILLION) 259
TABLE 231 JAPAN: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 259
TABLE 232 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 260
TABLE 233 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE,
2024–2031 (USD MILLION) 260
TABLE 234 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 261
TABLE 235 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 261
TABLE 236 JAPAN: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 262
TABLE 237 JAPAN: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 262
TABLE 238 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 263
TABLE 239 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY END USER,
2024–2031 (USD MILLION) 263
TABLE 240 CHINA: KEY MACRO INDICATORS 264
TABLE 241 CHINA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 264
TABLE 242 CHINA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2024–2031 (USD MILLION) 265
TABLE 243 CHINA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 265
TABLE 244 CHINA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 266
TABLE 245 CHINA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE,
2024–2031 (USD MILLION) 266
TABLE 246 CHINA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 267
TABLE 247 CHINA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 267
TABLE 248 CHINA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 268
TABLE 249 CHINA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 268
TABLE 250 CHINA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 269
TABLE 251 CHINA: VETERINARY PHARMACEUTICALS MARKET, BY END USER,
2024–2031 (USD MILLION) 269
TABLE 252 INDIA: KEY MACRO INDICATORS 270
TABLE 253 INDIA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 270
TABLE 254 INDIA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2024–2031 (USD MILLION) 271
TABLE 255 INDIA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 271
TABLE 256 INDIA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 272
TABLE 257 INDIA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE,
2024–2031 (USD MILLION) 272
TABLE 258 INDIA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 273
TABLE 259 INDIA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 273
TABLE 260 INDIA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 274
TABLE 261 INDIA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 274
TABLE 262 INDIA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 275
TABLE 263 INDIA: VETERINARY PHARMACEUTICALS MARKET, BY END USER,
2024–2031 (USD MILLION) 275
TABLE 264 AUSTRALIA: KEY MACRO INDICATORS 276
TABLE 265 AUSTRALIA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 276
TABLE 266 AUSTRALIA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 277
TABLE 267 AUSTRALIA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 277
TABLE 268 AUSTRALIA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 278
TABLE 269 AUSTRALIA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 278
TABLE 270 AUSTRALIA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 279
TABLE 271 AUSTRALIA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 279
TABLE 272 AUSTRALIA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 280
TABLE 273 AUSTRALIA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 280
TABLE 274 AUSTRALIA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 281
TABLE 275 AUSTRALIA: VETERINARY PHARMACEUTICALS MARKET, BY END USER,
2024–2031 (USD MILLION) 281
TABLE 276 SOUTH KOREA: KEY MACRO INDICATORS 282
TABLE 277 SOUTH KOREA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 282
TABLE 278 SOUTH KOREA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 283
TABLE 279 SOUTH KOREA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 283
TABLE 280 SOUTH KOREA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 284
TABLE 281 SOUTH KOREA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 284
TABLE 282 SOUTH KOREA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 285
TABLE 283 SOUTH KOREA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 285
TABLE 284 SOUTH KOREA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 286
TABLE 285 SOUTH KOREA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 286
TABLE 286 SOUTH KOREA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 287
TABLE 287 SOUTH KOREA: VETERINARY PHARMACEUTICALS MARKET, BY END USER,
2024–2031 (USD MILLION) 287
TABLE 288 PHILIPPINES: KEY MACRO INDICATORS 288
TABLE 289 PHILIPPINES: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 288
TABLE 290 PHILIPPINES: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 289
TABLE 291 PHILIPPINES: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 289
TABLE 292 PHILIPPINES: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 290
TABLE 293 PHILIPPINES: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 290
TABLE 294 PHILIPPINES: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 291
TABLE 295 PHILIPPINES: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 291
TABLE 296 PHILIPPINES: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 292
TABLE 297 PHILIPPINES: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 292
TABLE 298 PHILIPPINES: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 293
TABLE 299 PHILIPPINES: VETERINARY PHARMACEUTICALS MARKET, BY END USER,
2024–2031 (USD MILLION) 293
TABLE 300 REST OF ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 294
TABLE 301 REST OF ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS,
BY TYPE, 2024–2031 (USD MILLION) 294
TABLE 302 REST OF ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 295
TABLE 303 REST OF ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 295
TABLE 304 REST OF ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET,
BY FORMULATION TYPE, 2024–2031 (USD MILLION) 296
TABLE 305 REST OF ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET,
BY INDICATION, 2024–2031 (USD MILLION) 296
TABLE 306 REST OF ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET,
BY ANIMAL TYPE, 2024–2031 (USD MILLION) 297
TABLE 307 REST OF ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET
FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 297
TABLE 308 REST OF ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET
FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 297
TABLE 309 REST OF ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET,
BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 298
TABLE 310 REST OF ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET,
BY END USER, 2024–2031 (USD MILLION) 298
TABLE 311 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 299
TABLE 312 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 300
TABLE 313 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS) 300
TABLE 314 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 301
TABLE 315 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 301
TABLE 316 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 302
TABLE 317 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 302
TABLE 318 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 303
TABLE 319 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 303
TABLE 320 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 304
TABLE 321 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 304
TABLE 322 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 305
TABLE 323 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY END USER,
2024–2031 (USD MILLION) 305
TABLE 324 BRAZIL: KEY MACRO INDICATORS 306
TABLE 325 BRAZIL: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 306
TABLE 326 BRAZIL: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2024–2031 (USD MILLION) 307
TABLE 327 BRAZIL: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 307
TABLE 328 BRAZIL: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 308
TABLE 329 BRAZIL: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 308
TABLE 330 BRAZIL: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 309
TABLE 331 BRAZIL: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 309
TABLE 332 BRAZIL: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 310
TABLE 333 BRAZIL: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 310
TABLE 334 BRAZIL: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 311
TABLE 335 BRAZIL: VETERINARY PHARMACEUTICALS MARKET, BY END USER,
2024–2031 (USD MILLION) 311
TABLE 336 MEXICO: KEY MACRO INDICATORS 312
TABLE 337 MEXICO: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 312
TABLE 338 MEXICO: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2024–2031 (USD MILLION) 313
TABLE 339 MEXICO: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 313
TABLE 340 MEXICO: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 314
TABLE 341 MEXICO: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 314
TABLE 342 MEXICO: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 315
TABLE 343 MEXICO: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 315
TABLE 344 MEXICO: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 316
TABLE 345 MEXICO: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 316
TABLE 346 MEXICO: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 317
TABLE 347 MEXICO: VETERINARY PHARMACEUTICALS MARKET, BY END USER,
2024–2031 (USD MILLION) 317
TABLE 348 REST OF LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 318
TABLE 349 REST OF LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 318
TABLE 350 REST OF LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 319
TABLE 351 REST OF LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 319
TABLE 352 REST OF LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET,
BY FORMULATION TYPE, 2024–2031 (USD MILLION) 320
TABLE 353 REST OF LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET,
BY INDICATION, 2024–2031 (USD MILLION) 320
TABLE 354 REST OF LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 321
TABLE 355 REST OF LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 321
TABLE 356 REST OF LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 321
TABLE 357 REST OF LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET,
BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 322
TABLE 358 REST OF LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET,
BY END USER, 2024–2031 (USD MILLION) 322
TABLE 359 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 323
TABLE 360 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 323
TABLE 361 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS) 324
TABLE 362 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 324
TABLE 363 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 325
TABLE 364 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 325
TABLE 365 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET,
BY FORMULATION TYPE, 2024–2031 (USD MILLION) 326
TABLE 366 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET,
BY INDICATION, 2024–2031 (USD MILLION) 326
TABLE 367 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 327
TABLE 368 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 327
TABLE 369 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 327
TABLE 370 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET,
BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 328
TABLE 371 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET,
BY END USER, 2024–2031 (USD MILLION) 328
TABLE 372 GCC COUNTRIES: VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 329
TABLE 373 GCC COUNTRIES: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 329
TABLE 374 GCC COUNTRIES: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS,
BY TYPE, 2024–2031 (USD MILLION) 330
TABLE 375 GCC COUNTRIES: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 330
TABLE 376 GCC COUNTRIES: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 331
TABLE 377 GCC COUNTRIES: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 331
TABLE 378 GCC COUNTRIES: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 332
TABLE 379 GCC COUNTRIES: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION) 332
TABLE 380 GCC COUNTRIES: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 333
TABLE 381 GCC COUNTRIES: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 333
TABLE 382 GCC COUNTRIES: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 334
TABLE 383 GCC COUNTRIES: VETERINARY PHARMACEUTICALS MARKET, BY END USER,
2024–2031 (USD MILLION) 334
TABLE 384 KINGDOM OF SAUDI ARABIA (KSA): KEY MACRO INDICATORS 335
TABLE 385 KSA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 335
TABLE 386 KSA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2024–2031 (USD MILLION) 336
TABLE 387 KSA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 336
TABLE 388 KSA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 337
TABLE 389 KSA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE,
2024–2031 (USD MILLION) 337
TABLE 390 KSA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 338
TABLE 391 KSA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 338
TABLE 392 KSA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 339
TABLE 393 KSA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 339
TABLE 394 KSA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 340
TABLE 395 KSA: VETERINARY PHARMACEUTICALS MARKET, BY END USER,
2024–2031 (USD MILLION) 340
TABLE 396 UNITED ARAB EMIRATES (UAE): KEY MACRO INDICATORS 341
TABLE 397 UAE: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE,
2024–2031 (USD MILLION) 341
TABLE 398 UAE: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE,
2024–2031 (USD MILLION) 342
TABLE 399 UAE: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 342
TABLE 400 UAE: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 343
TABLE 401 UAE: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE,
2024–2031 (USD MILLION) 343
TABLE 402 UAE: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 344
TABLE 403 UAE: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 344
TABLE 404 UAE: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 345
TABLE 405 UAE: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS,
BY TYPE, 2024–2031 (USD MILLION) 345
TABLE 406 UAE: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 346
TABLE 407 UAE: VETERINARY PHARMACEUTICALS MARKET, BY END USER,
2024–2031 (USD MILLION) 346
TABLE 408 REST OF GCC: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION) 347
TABLE 409 REST OF GCC: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 347
TABLE 410 REST OF GCC: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 348
TABLE 411 REST OF GCC: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 348
TABLE 412 REST OF GCC: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION) 349
TABLE 413 REST OF GCC: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION,
2024–2031 (USD MILLION) 349
TABLE 414 REST OF GCC: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE,
2024–2031 (USD MILLION) 350
TABLE 415 REST OF GCC: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 350
TABLE 416 REST OF GCC: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 350
TABLE 417 REST OF GCC: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 351
TABLE 418 REST OF GCC: VETERINARY PHARMACEUTICALS MARKET, BY END USER,
2024–2031 (USD MILLION) 351
TABLE 419 REST OF MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET,
BY PRODUCT TYPE, 2024–2031 (USD MILLION) 352
TABLE 420 REST OF MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION) 352
TABLE 421 REST OF MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION) 353
TABLE 422 REST OF MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET,
BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION) 353
TABLE 423 REST OF MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET,
BY FORMULATION TYPE, 2024–2031 (USD MILLION) 354
TABLE 424 REST OF MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET,
BY INDICATION, 2024–2031 (USD MILLION) 354
TABLE 425 REST OF MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET,
BY ANIMAL TYPE, 2024–2031 (USD MILLION) 355
TABLE 426 REST OF MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 355
TABLE 427 REST OF MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION) 355
TABLE 428 REST OF MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET,
BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION) 356
TABLE 429 REST OF MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET,
BY END USER, 2024–2031 (USD MILLION) 356
TABLE 430 VETERINARY PHARMACEUTICALS MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, 2023–2026 357
TABLE 431 VETERINARY PHARMACEUTICALS MARKET: DEGREE OF COMPETITION 360
TABLE 432 VETERINARY PHARMACEUTICALS MARKET: REGION FOOTPRINT 367
TABLE 433 VETERINARY PHARMACEUTICALS MARKET: PRODUCT TYPE FOOTPRINT 368
TABLE 434 VETERINARY PHARMACEUTICALS MARKET: ROUTE OF ADMINISTRATION FOOTPRINT 369
TABLE 435 VETERINARY PHARMACEUTICALS MARKET: INDICATION FOOTPRINT 370
TABLE 436 VETERINARY PHARMACEUTICALS MARKET: END USER FOOTPRINT 371
TABLE 437 VETERINARY PHARMACEUTICALS MARKET: KEY STARTUPS/SMES 374
TABLE 438 VETERINARY PHARMACEUTICALS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 375
TABLE 439 VETERINARY PHARMACEUTICALS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–JANUARY 2026 377
TABLE 440 VETERINARY PHARMACEUTICALS MARKET: DEALS, JANUARY 2023–JANUARY 2026 378
TABLE 441 VETERINARY PHARMACEUTICALS MARKET: EXPANSIONS,
JANUARY 2023–JANUARY 2026 379
TABLE 442 VETERINARY PHARMACEUTICALS MARKET: OTHER DEVELOPMENTS, JANUARY 2023–JANUARY 2026 379
TABLE 443 ZOETIS INC.: COMPANY OVERVIEW 380
TABLE 444 ZOETIS INC.: PRODUCTS OFFERED 382
TABLE 445 ZOETIS, INC.: PRODUCT LAUNCHES & APPROVALS 383
TABLE 446 ZOETIS, INC.: EXPANSIONS 384
TABLE 447 ZOETIS, INC.: OTHER DEVELOPMENTS 384
TABLE 448 MERCK & CO., INC.: COMPANY OVERVIEW 386
TABLE 449 MERCK & CO., INC.: PRODUCTS OFFERED 387
TABLE 450 MERCK & CO., INC.: PRODUCT LAUNCHES & APPROVALS 388
TABLE 451 MERCK & CO., INC.: DEALS 389
TABLE 452 MERCK & CO., INC.: EXPANSIONS 390
TABLE 453 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW 392
TABLE 454 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED 393
TABLE 455 BOEHRINGER INGELHEIM INTERNATIONAL GMBH:
PRODUCT LAUNCHES & APPROVALS 394
TABLE 456 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: DEALS 395
TABLE 457 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: EXPANSIONS 396
TABLE 458 ELANCO ANIMAL HEALTH INCORPORATED: COMPANY OVERVIEW 398
TABLE 459 ELANCO ANIMAL HEALTH INCORPORATED: PRODUCTS OFFERED 399
TABLE 460 ELANCO ANIMAL HEALTH INCORPORATED: PRODUCT LAUNCHES & APPROVALS 401
TABLE 461 ELANCO ANIMAL HEALTH INCORPORATED: EXPANSIONS 402
TABLE 462 ELANCO ANIMAL HEALTH INCORPORATED: OTHER DEVELOPMENTS 403
TABLE 463 VIRBAC: COMPANY OVERVIEW 404
TABLE 464 VIRBAC: PRODUCTS OFFERED 405
TABLE 465 VIRBAC: PRODUCT LAUNCHES & APPROVALS 406
TABLE 466 VIRBAC: DEALS 407
TABLE 467 VIRBAC: EXPANSIONS 408
TABLE 468 CEVA: COMPANY OVERVIEW 409
TABLE 469 CEVA: PRODUCTS OFFERED 410
TABLE 470 CEVA: DEALS 410
TABLE 471 CEVA: EXPANSIONS 411
TABLE 472 VETOQUINOL: COMPANY OVERVIEW 412
TABLE 473 VETOQUINOL: PRODUCTS OFFERED 413
TABLE 474 VETOQUINOL: PRODUCT LAUNCHES & APPROVALS 415
TABLE 475 VETOQUINOL: DEALS 415
TABLE 476 DECHRA PHARMACEUTICALS PLC: COMPANY OVERVIEW 416
TABLE 477 DECHRA PHARMACEUTICALS PLC: PRODUCTS OFFERED 416
TABLE 478 DECHRA PHARMACEUTICALS PLC: PRODUCT LAUNCHES & APPROVALS 418
TABLE 479 DECHRA PHARMACEUTICALS PLC: DEALS 419
TABLE 480 DECHRA PHARMACEUTICALS PLC: OTHER DEVELOPMENTS 419
TABLE 481 NORBROOK: COMPANY OVERVIEW 420
TABLE 482 NORBROOK: PRODUCTS OFFERED 420
TABLE 483 NORBROOK: PRODUCT LAUNCHES & APPROVALS 423
TABLE 484 NORBROOK: DEALS 423
TABLE 485 NORBROOK: EXPANSIONS 424
TABLE 486 NORBROOK: OTHER DEVELOPMENTS 424
TABLE 487 BIMEDA CORPORATE: COMPANY OVERVIEW 425
TABLE 488 BIMEDA CORPORATE: PRODUCTS OFFERED 425
TABLE 489 BIMEDA CORPORATE: PRODUCT LAUNCHES & APPROVALS 427
TABLE 490 BIMEDA CORPORATE: DEALS 428
TABLE 491 BIMEDA CORPORATE: EXPANSIONS 428
TABLE 492 HESTER BIOSCIENCES LIMITED: COMPANY OVERVIEW 429
TABLE 493 HESTER BIOSCIENCES LIMITED: PRODUCTS OFFERED 430
TABLE 494 INDIAN IMMUNOLOGICALS LTD.: COMPANY OVERVIEW 432
TABLE 495 INDIAN IMMUNOLOGICALS LTD.: PRODUCTS OFFERED 433
TABLE 496 ANIMALCARE GROUP PLC: COMPANY OVERVIEW 435
TABLE 497 ANIMALCARE GROUP PLC: PRODUCTS OFFERED 437
TABLE 498 ANIMALCARE GROUP PLC.: DEALS 438
TABLE 499 ANIMALCARE GROUP PLC: PRODUCT LAUNCHES & APPROVALS 439
TABLE 500 KYORITSU SEIYAKU CORPORATION: COMPANY OVERVIEW 440
TABLE 501 KYORITSU SEIYAKU CORPORATION: PRODUCTS OFFERED 440
TABLE 502 KYORITSU SEIYAKU CORPORATION: PRODUCT LAUNCHES & APPROVALS 442
TABLE 503 KYORITSU SEIYAKU CORPORATION: DEALS 443
TABLE 504 CALIER: COMPANY OVERVIEW 444
TABLE 505 CALIER: PRODUCTS OFFERED 444
TABLE 506 CALIER: PRODUCT LAUNCHES & APPROVALS 446

LIST OF FIGURES

FIGURE 1 VETERINARY PHARMACEUTICALS MARKET SEGMENTATION 42
FIGURE 2 MARKET SCENARIO 45
FIGURE 3 VETERINARY PHARMACEUTICALS MARKET, 2024–2031 46
FIGURE 4 VETERINARY PHARMACEUTICALS MARKET: MAJOR STRATEGIES ADOPTED
BY KEY PLAYERS, 2022–2025 46
FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF VETERINARY
PHARMACEUTICALS MARKET 47
FIGURE 6 VETERINARY PHARMACEUTICALS MARKET: HIGH-GROWTH SEGMENTS,
2026–2031 48
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 49
FIGURE 8 INCREASING PET CARE EXPENDITURE TO DRIVE MARKET 50
FIGURE 9 DRUGS SEGMENT AND CHINA DOMINATED MARKET IN 2025 51
FIGURE 10 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 52
FIGURE 11 DEVELOPING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 52
FIGURE 12 VETERINARY PHARMACEUTICALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 53
FIGURE 13 PET POPULATION IN MAJOR MARKETS, 2022 (MILLION) 54
FIGURE 14 EUROPE: PET POPULATION, 2021–2023 56
FIGURE 15 VETERINARY PHARMACEUTICALS MARKET: PORTER’S FIVE FORCES ANALYSIS 65
FIGURE 16 VETERINARY PHARMACEUTICALS MARKET: VALUE CHAIN ANALYSIS 71
FIGURE 17 VETERINARY PHARMACEUTICALS MARKET: SUPPLY CHAIN ANALYSIS 72
FIGURE 18 VETERINARY PHARMACEUTICALS MARKET: ECOSYSTEM ANALYSIS 73
FIGURE 19 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS 79
FIGURE 20 INVESTMENT/VENTURE CAPITAL SCENARIO IN VETERINARY PHARMACEUTICALS MARKET, 2021–2025 80
FIGURE 21 PATENTS APPLIED AND GRANTED, JANUARY 2015–DECEMBER 2025 90
FIGURE 22 TOP APPLICANT COUNTRIES/REGIONS FOR VETERINARY PHARMACEUTICALS PRODUCTS, JANUARY 2015–DECEMBER 2025 91
FIGURE 23 VETERINARY PHARMACEUTICALS MARKET: DECISION-MAKING FACTORS 102
FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR VETERINARY PHARMACEUTICAL PRODUCTS 103
FIGURE 25 KEY BUYING CRITERIA FOR TOP THREE END USERS 104
FIGURE 26 ADOPTION BARRIERS AND INTERNAL CHALLENGES 105
FIGURE 27 VETERINARY PHARMACEUTICALS MARKET: GEOGRAPHIC SNAPSHOT 184
FIGURE 28 NORTH AMERICA: EXPECTED GROWTH IN NUMBER OF
VETERINARIANS, 2020–2030 188
FIGURE 29 NORTH AMERICA: PET POPULATION, 2024 (MILLION) 188
FIGURE 30 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET SNAPSHOT 189
FIGURE 31 US: TOTAL PET HEALTH EXPENDITURE, 2020–2024 196
FIGURE 32 EUROPE: PET POPULATION, 2023 (MILLION) 208
FIGURE 33 ASIA PACIFIC: DOG POPULATION, BY COUNTRY, 2024 250
FIGURE 34 ASIA PACIFIC: CAT POPULATION, BY COUNTRY, 2024 251
FIGURE 35 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET SNAPSHOT 251
FIGURE 36 VETERINARY PHARMACEUTICALS MARKET: REVENUE ANALYSIS
OF KEY PLAYERS, 2023−2025 359
FIGURE 37 VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025 360
FIGURE 38 US: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025 361
FIGURE 39 EUROPE: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025 362
FIGURE 40 BRAND/PRODUCT COMPARATIVE ANALYSIS 363
FIGURE 41 VETERINARY PHARMACEUTICALS MARKET: COMPANY EVALUATION
MATRIX (KEY PLAYERS), 2025 365
FIGURE 42 VETERINARY PHARMACEUTICALS MARKET: COMPANY FOOTPRINT 366
FIGURE 43 VETERINARY PHARMACEUTICALS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 373
FIGURE 44 EV/EBITDA OF KEY VENDORS 376
FIGURE 45 5-YEAR STOCK BETA OF KEY VENDORS 376
FIGURE 46 ZOETIS INC.: COMPANY SNAPSHOT (2025) 381
FIGURE 47 MERCK & CO., INC.: COMPANY SNAPSHOT (2025) 387
FIGURE 48 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2025) 393
FIGURE 49 ELANCO ANIMAL HEALTH INCORPORATED: COMPANY SNAPSHOT (2025) 399
FIGURE 50 VIRBAC: COMPANY SNAPSHOT (2025) 405
FIGURE 51 CEVA: COMPANY SNAPSHOT (2025) 409
FIGURE 52 VETOQUINOL: COMPANY SNAPSHOT (2025) 413
FIGURE 53 HESTER BIOSCIENCES LIMITED: COMPANY SNAPSHOT (2025) 430
FIGURE 54 INDIAN IMMUNOLOGICALS LTD.: COMPANY SNAPSHOT (2025) 432
FIGURE 55 ANIMALCARE GROUP PLC: COMPANY SNAPSHOT 436
FIGURE 56 RESEARCH DESIGN 457
FIGURE 57 PRIMARY SOURCES 460
FIGURE 58 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS 461
FIGURE 59 BREAKDOWN OF PRIMARY INTERVIEWS: DEMAND-SIDE PARTICIPANTS 462
FIGURE 60 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 462
FIGURE 61 MARKET SIZE ESTIMATION APPROACH: REVENUE SHARE ANALYSIS 463
FIGURE 62 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2025) 463
FIGURE 63 VETERINARY PHARMACEUTICALS MARKET: SUPPLY-SIDE ANALYSIS 464
FIGURE 64 TOP-DOWN APPROACH 465
FIGURE 65 VETERINARY PHARMACEUTICALS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2026–2031) 466
FIGURE 66 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS OF VETERINARY PHARMACEUTICALS MARKET (2026-2031) 467
FIGURE 67 DATA TRIANGULATION 469

---

---